Caxton Associates (New York)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Caxton Associates (New York)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$590K	Buy	+1,797	New	+$610K	0.02%	301
2024 Q3	–	Sell	-3,785	Closed	-$1.03M	–	529
2024 Q2	$1.03M	Buy	+3,785	New	+$1.1M	0.04%	243
2024 Q1	–	Sell	-10,677	Closed	-$3.45M	–	468
2023 Q4	$3.45M	Buy	10,677 +8,813	+473%	+$2.76M	0.18%	72
2023 Q3	$668K	Buy	+1,864	New	+$719K	0.09%	208
2023 Q1	–	Sell	-2,822	Closed	-$1.19M	–	501
2022 Q4	$1.19M	Buy	2,822 +2,003	+245%	+$808K	0.08%	91
2022 Q3	$342K	Sell	819 -488	-37%	-$243K	0.05%	303
2022 Q2	$647K	Buy	1,307 +754	+136%	+$393K	0.06%	211
2022 Q1	$311K	Sell	553 -129	-19%	-$77.8K	0.03%	355
2021 Q4	$515K	Buy	+682	New	+$510K	0.05%	265
2021 Q3	–	Sell	-1,234	Closed	-$795K	–	453
2021 Q2	$795K	Buy	1,234 +253	+26%	+$154K	0.09%	101
2021 Q1	$560K	Buy	+981	New	+$581K	0.05%	143
2017 Q3	–	Sell	-2,903	Closed	-$657K	–	495
2017 Q2	$657K	Buy	+2,903	New	+$633K	0.03%	236

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Caxton Associates (New York)'s BIO Position: Q4 2024 in Review

Caxton Associates (New York) opened a new position in Bio-Rad Laboratories Class A (BIO) in Q4 2024: 1,797 shares worth $590K. The stake represents 0.02% of the portfolio and ranks #301 among its holdings. This is a return to the name: Caxton Associates (New York) previously reported a position in BIO as recently as Q2 2024.

Caxton Associates (New York) first reported a position in BIO in Q2 2017 and has held it in 12 quarters since. The position peaked at $3.45M in Q4 2023. 457 funds tracked by Wall St. Rank hold BIO as of Q4 2024.

Caxton Associates (New York) held 1,797 shares of Bio-Rad Laboratories Class A worth $590K as of Q4 2024.
Bio-Rad Laboratories Class A was a new Caxton Associates (New York) position in Q4 2024.
Bio-Rad Laboratories Class A made up 0.02% of Caxton Associates (New York)'s portfolio in Q4 2024, its #301 holding.
Caxton Associates (New York) first reported a position in Bio-Rad Laboratories Class A in Q2 2017 and has held it in 12 quarters since.
Caxton Associates (New York)'s Bio-Rad Laboratories Class A position peaked at $3.45M in Q4 2023.
457 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.